Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11401374 | 0.89 | TP53 (0.47) | TP53 | |
| SCHEMBL44773 | 0.78 | TP53 (0.48) | TP53 | |
| SCHEMBL17915946 | 0.75 | TP53 (0.43) | TP53TSHRHRH3 | |
| SCHEMBL24527435 | 0.75 | ACHE (0.44) | TP53TSHRAKR1C3HRH3 | |
| SCHEMBL8600641 | 0.71 | ALDH1A1 (0.41) | TP53TSHR | |
| SCHEMBL11186135 | 0.67 | MEN1 (0.44) | TP53TSHR | |
| SCHEMBL24527388 | 0.67 | ALOX5 (0.37) | TP53 | |
| SCHEMBL10655726 | 0.66 | ADRA2C (0.47) | TP53TSHR | |
| SCHEMBL31252540 | 0.64 | AKR1C3 (0.57) | CYP2A6AKR1C3 | |
| SCHEMBL14038465 | 0.62 | LMNA (0.33) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101910136-B | Fluorescent agent having ethynyl group | NIPPON CHEMICAL WORKS | 2012-08-15 | — | — | CN | disclosed |
| US-7875644-B2 | tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas | MERCK PATENT GMBH (DE) | 2011-01-25 | — | — | US | disclosed |
| CN-101910136-A | Fluorescent agent having ethynyl group | NIPPON CHEMICAL WORKS | 2010-12-08 | — | — | CN | disclosed |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MET, FLT3, ERBB3 | TP53 295/4885FAAH 1253/4885MGLL 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.